Genetically modified animal models of hereditary diseases for testing of gene-directed therapy

Авторы

  • Anna V. Polikarpova Institute of Gene Biology, Laboratory of modeling and gene therapy of hereditary diseases, Russian Academy of Sciences; Marlin Biotech LLC ORCID logo https://orcid.org/0000-0001-9442-8371
  • Tatiana V. Egorova Institute of Gene Biology, Laboratory of modeling and gene therapy of hereditary diseases, Russian Academy of Sciences; Marlin Biotech LLC
  • Maryana V. Bardina Institute of Gene Biology, Laboratory of modeling and gene therapy of hereditary diseases, Russian Academy of Sciences; Marlin Biotech LLC; Institute of Gene Biology, Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Russian Academy of Sciences ORCID logo https://orcid.org/0000-0003-1976-4767

DOI:

https://doi.org/10.3897/rrpharmacology.8.82618

Аннотация

Disease-causing genes have been identified for many severe muscular and neurological genetic disorders. Advances in the gene therapy field offer promising solutions for drug development to treat these life-threatening conditions. Depend­ing on how the mutation affects the function of the gene product, different gene therapy approaches may be beneficial. Gene replacement therapy is appropriate for diseases caused by mutations that result in the deficiency of the functional protein. Gene suppression strategy is suggested for disorders caused by the toxic product of the mutant gene. Splicing modulators, genome editing, and base editing techniques can be applied to disorders with different types of underlying mutations. Testing potential drugs in animal models of human diseases is an indispensable step of development. Given the specific gene therapy approach, appropriate animal models can be generated using a variety of technologies ranging from transgenesis to precise genome editing. In this review, we discuss technologies used to generate small and large animal models of the most common muscular and neurological genetic disorders. We specifically focus on animal mod­els that were used to test gene therapies based on adeno-associated vectors and antisense nucleotides.

Ключевые слова:

animal models of human diseases, gene therapy, antisense oligonucleotides (ASO), hereditary diseases, adeno-associated virus (AAV), CRISPR/Cas9, transgenesis

Вклад авторов

Anna V. Polikarpova, Institute of Gene Biology, Laboratory of modeling and gene therapy of hereditary diseases, Russian Academy of Sciences; Marlin Biotech LLC

PhD in Biology, Research Fellow.

Tatiana V. Egorova, Institute of Gene Biology, Laboratory of modeling and gene therapy of hereditary diseases, Russian Academy of Sciences; Marlin Biotech LLC

Research Fellow.

Maryana V. Bardina, Institute of Gene Biology, Laboratory of modeling and gene therapy of hereditary diseases, Russian Academy of Sciences; Marlin Biotech LLC; Institute of Gene Biology, Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Russian Academy of Sciences

PhD in Biology, head of the laboratory.

Загрузки

Опубликован

14.06.2022

Как цитировать

Polikarpova AV, Egorova TV, Bardina MV (2022) Genetically modified animal models of hereditary diseases for testing of gene-directed therapy. Research Results in Pharmacology 8(2): 11–26. https://doi.org/10.3897/rrpharmacology.8.82618

Выпуск

Раздел

Обзорная статья